Antibodies and related molecules that bind to 161P2F10B proteins

• US 7,427,399 B2
• Filed: 03/31/2006
• Issued: 09/23/2008
• Est. Priority Date: 11/07/2001
• Status: Expired due to Fees

• Current Assignee: Agensys, Inc. (Astellas Pharma Incorporated)
• Original Assignee: Agensys, Inc. (Astellas Pharma Incorporated)
• Inventors: Gudas, Jean, Raitano, Arthur B., Morrison, Karen Jane Meyrick, Morrison, Robert Kendall, Satpaev, Daulet, Challita-Eid, Pia M., Perez-Villar, Juan J., Jakobovits, Aya, Kanner, Steven B., Jia, Xiao-chi
• Primary Examiner(s): Ungar; Susan
• Assistant Examiner(s): Goddard; Laura B
• Application Number:
  US11/396,178
• Publication Number:
  US 20060275211A1
• Time in Patent Office: 907 Days
• Field of Search: None
• US Class Current: 424/138.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 31/7088 Compounds having three or more nucleosides or nucleotides
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61K 51/1045 against animal or human tumor cells or tumor cell determinants
• CPC Class Codes: A61P 13/08 of the prostate
• CPC Class Codes: A61P 13/10 of the bladder
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: C07K 14/47 from mammals
• CPC Class Codes: C07K 16/18 against material from animals or humans
• CPC Class Codes: C07K 16/30 from tumour cells
• CPC Class Codes: C07K 16/3023 Lung
• CPC Class Codes: C07K 16/303 Liver or Pancreas
• CPC Class Codes: C07K 16/3038 Kidney, bladder
• CPC Class Codes: C07K 16/3046 Stomach, Intestines
• CPC Class Codes: C07K 16/3061 Blood cells
• CPC Class Codes: C07K 16/3069 Reproductive system, e.g. ovaria, uterus, testes, prostate
• CPC Class Codes: C07K 16/40 against enzymes
• CPC Class Codes: C07K 2317/20 characterized by taxonomic origin
• CPC Class Codes: C07K 2317/33 Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
• CPC Class Codes: C07K 2317/34 : Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
• CPC Class Codes: C07K 2317/54 : F(ab')2
• CPC Class Codes: C07K 2317/55 : Fab or Fab'
• CPC Class Codes: C07K 2317/73 : Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
• CPC Class Codes: C07K 2317/76 : Antagonist effect on antigen, e.g. neutralization or inhibition of binding
• CPC Class Codes: C07K 2317/77 : Internalization into the cell
• CPC Class Codes: C07K 2319/30 : Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
• CPC Class Codes: C12N 9/16 : acting on ester bonds (3.1)
• CPC Class Codes: C12Q 1/6886 : for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/158 : Expression markers
• CPC Class Codes: G01N 33/57492 : involving compounds localized on the membrane of tumor or cancer cells
• CPC Class Codes: Y02A 50/30 : Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Antibodies and molecules derived therefrom that bind to 161P2F10B protein and variants thereof, are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P2F10B gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 161P2F10B can be used in active or passive immunization.

Claims

1. A monoclonal antibody or fragment thereof comprising an antigen binding site that binds specifically to 161P2F10B protein comprising the amino acid sequence of SEQ ID NO:

2, and wherein the monoclonal antibody comprises the V_H region of SEQ ID NO;

139, from residue 1 to 114 and the V_L region of SEQ ID NO;

140, from residue 1 to 108.

2. The antibody or fragment of claim 1, wherein the antibody is assigned A.T.C.C. Accession No.:

PTA-7452.

3. The antibody or fragment of claim 1, wherein the monoclonal antibody is a humanized antibody.

4. The antibody or fragment of claim 1, wherein the fragment is an Fab, F(ab′

)₂, Fv or Sfv fragment.

5. The antibody or fragment of claim 1, wherein the antibody is a fully human antibody.

6. The antibody or fragment of claim 1, wherein the antigen binding site is a murine antigen binding domain.

7. The antibody or fragment of claim 1, which is recombinantly produced.

8. The antibody or fragment of claim 7, wherein the recombinant protein comprises the antigen binding region.

9. The antibody or fragment of claim 1, wherein the antibody is coupled to a detectable marker, a toxin, a therapeutic agent, or a chemotherapeutic agent.

10. The antibody or fragment of claim 9, wherein the detectable marker is a radioisotope, a metal chelator, an enzyme, a fluorescent compound, a bioluminescent compound or a chemiluminescent compound.

11. The antibody or fragment of claim 10, wherein the radioisotope comprises ²¹²Bi, ¹³¹I, ¹³¹In, ⁹⁰Y, ¹⁸⁶Re, ²¹¹At, ¹²⁵I, ¹⁸⁸Re, ¹⁵³Sm, ²¹³Bi, ³²P, or Lu.

12. The antibody or fragment of claim 9, wherein the toxin comprises ricin, ricin A chain, doxorubicin, daunorubicin, a maytansinoid, taxol, ethidium bromide, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicine, dihydroxy anthracin dione, actinomycin, diphtheria toxin, Pseudomonas exotoxin (PE) A, PE40, abrin, abrin A chain, modeccin A chain, alpha sarcin, gelonin, mitogellin, retstrictocin, phenomycin, enomycin, curicin, crotin, calicheamicin, sapaonaria officinalis inhibitor, glucocorticoid, auristatin, auromycin, yttrium, bismuth, combrestatin, duocarmycins, dolostatin, cc1065, or a cisplatin.

13. A hybridoma that produces the monoclonal antibody of claim 1.

14. A pharmaceutical composition that comprises the antibody or fragment of claim 1 in a human unit dose form.

15. A method of delivering a cytotoxic agent or a diagnostic agent to a cell that expresses a 161P2F10B protein comprising the amino acid sequence of SEQ ID NO:

2, comprising;

providing a cytotoxic agent or a diagnostic agent conjugated to the antibody or fragment of claim 1, to form an antibody agent or fragment agent conjugate; and

,

exposing the cell to the antibody agent or fragment agent conjugate.

16. The method of claim 15, wherein the cytotoxic agent or the diagnostic agent is selected from the group consisting of a detectable marker, a toxin, and a therapeutic agent.

17. The method of claim 16, wherein the detectable marker is a radioisotope, a metal chelator, an enzyme, a fluorescent compound, a bioluminescent compound or a chemiluminescent compound.

18. The method of claim 17, wherein the radioisotope comprises ²¹²Bi, ¹³¹I, ¹³¹In, ⁹⁰Y, ¹⁸⁶Re, ²¹¹At, ¹²⁵I, ¹⁸⁸Re, ¹⁵³Sm, ²¹³Bi, ³²P, or Lu.

19. The method of claim 16, wherein the toxin comprises ricin, ricin A chain, doxorubicin, daunorubicin, a maytansinoid, taxol, ethidium bromide, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicine, dihydroxy anthracin dione, actinomycin, diphtheria toxin, Pseudomonas exotoxin (PE) A, PE40, abrin, abrin A chain, modeccin A chain, alpha sarcin, gelonin, mitogellin, retstrictocin, phenomycin, enomycin, curicin, crotin, calicheamicin, sapaonaria officinalis inhibitor, glucocorticoid, auristatins, auromycin, yttrium, bismuth, combrestatin, duocarmycins, dolostatin, cc1065, or a cisplatin.

20. A method for detecting a 161P2F10B protein comprising the amino acid sequence of SEQ ID NO:

2 in a biological sample, comprising steps of;

providing the biological sample and a control sample;

contacting the biological sample and the control sample with the antibody of claim 1 that specifically binds to the 161P2F10B protein; and

determining an amount of a complex of the substance with the 161P2F10B protein and the antibody present in the biological sample and the control sample.

21. The method of claim 20 further comprising:

taking the biological sample and the control sample from a patient who has or is suspected of having a cancer in a tissue selected from the group consisting of prostate, kidney, colon, lung, ovary, breast, lymphoma, bone, uterus, pancreas, and liver.